SSG
GMAB icon

Summit Securities Group’s Genmab GMAB Stock Holding History

Summit Securities Group’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-152,832
Closed -$3.16M – 1150
2025
Q2 		$3.16M Buy
+152,832
New +$3.14M 0.61% 31
2023
Q3 		– Sell
-5,551
Closed -$2.1M – 750
2023
Q2 		$2.1M Sell
5,551
-71,439
-93% -$2.85M 0.27% 62
2023
Q1 		$2.91M Buy
+76,990
New +$2.96M 0.24% 54

Other funds holding GMAB

OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Summit Securities Group's GMAB Position: Q3 2025 in Review

Summit Securities Group sold out of Genmab (GMAB) in Q3 2025, closing a stake of 152,832 shares — an estimated $3.16M sold.

Summit Securities Group first reported a position in GMAB in Q1 2023 and held it in 3 quarters. The position peaked at $3.16M in Q2 2025. 252 funds tracked by Wall St. Rank hold GMAB as of Q3 2025.

  • Summit Securities Group reported no remaining Genmab position as of Q3 2025 after selling out during the quarter.
  • Summit Securities Group sold 152,832 Genmab shares in Q3 2025, an estimated $3.16M.
  • Summit Securities Group first reported a position in Genmab in Q1 2023 and held it in 3 quarters.
  • Summit Securities Group's Genmab position peaked at $3.16M in Q2 2025.
  • 252 funds tracked by Wall St. Rank held Genmab as of Q3 2025.

Based on Summit Securities Group's 13F filing for Q3 2025, filed 13 Nov 2025.